This protocol addresses the specific subpopulation of patients with BCR-ABL1-positive acute myeloid leukemia (AML) — a molecularly defined subtype for which available clinical evidence remains limited. Management decisions in this setting require careful consideration of the prior treatment response.
Patients in this scenario previously received a tyrosine-kinase inhibitor (TKI), with or without induction chemotherapy, as first-line therapy for BCR-ABL1-positive AML. Escalation to this protocol is triggered when the primary goal of that line — achievement of remission — was not reached.
For patients who did not respond to the initial tyrosine-kinase inhibitor, the approach centres on a different agent within the same therapeutic class. Full selection criteria, sequencing, and supporting measures are available in the complete structured protocol.